Drano: What do you make of this from Friday? I
Post# of 72447
Posted On: 03/06/2016 5:59:25 AM
Drano:
What do you make of this from Friday? I can't tell if results are good or just more of the same in the psoriasis world. I recognize it is not exactly what P is attempting to treat...I also don't know if it is orally administered or through IV/injection.
4:19 pm Eli Lilly reports Ixekizumab demonstrates rapid, clinically meaningful improvements as early as 1 week among patients with moderate-to-severe plaque psoriasis (LLY) :
•Significant differences in mean percentage improvement of psoriasis plaques were observed among patients treated with ixekizumab compared to etanercept and placebo: At one week, the mean percentage improvement was 32.7 percent in the group randomized to receive ixekizumab every two weeks, 10.3 percent in etanercept and 5.31 percent in placebo (p
• Treatment with ixekizumab also resulted in clinically meaningful improvements (PASI 50) as early as one week, which were statistically significantly different compared with etanercept and placebo. At one week, PASI 50 was achieved by 22.8 percent of patients treated with ixekizumab every two weeks compared to 3.9 percent among those treated with etanercept and 1.4 percent in placebo (p
•The majority of treatment-emergent adverse events were mild or moderate.
What do you make of this from Friday? I can't tell if results are good or just more of the same in the psoriasis world. I recognize it is not exactly what P is attempting to treat...I also don't know if it is orally administered or through IV/injection.
4:19 pm Eli Lilly reports Ixekizumab demonstrates rapid, clinically meaningful improvements as early as 1 week among patients with moderate-to-severe plaque psoriasis (LLY) :
•Significant differences in mean percentage improvement of psoriasis plaques were observed among patients treated with ixekizumab compared to etanercept and placebo: At one week, the mean percentage improvement was 32.7 percent in the group randomized to receive ixekizumab every two weeks, 10.3 percent in etanercept and 5.31 percent in placebo (p
• Treatment with ixekizumab also resulted in clinically meaningful improvements (PASI 50) as early as one week, which were statistically significantly different compared with etanercept and placebo. At one week, PASI 50 was achieved by 22.8 percent of patients treated with ixekizumab every two weeks compared to 3.9 percent among those treated with etanercept and 1.4 percent in placebo (p
•The majority of treatment-emergent adverse events were mild or moderate.
(0)
(0)